

Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/583,573
<b>Filing Date</b>	June 19, 2006
<b>First Named Inventor</b>	Maria Fardis
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown

Sheet 1 of 6

01692.258US2

**US PATENT DOCUMENTS**

Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document
	US 5,413,996	05-09-1995	Bodor, Nicholas S.
	US 5,670,497	09-23-1997	Bold, Guido <i>et al.</i>
	US 5,750,493	05-12-1998	Schinazi, Raymond F. <i>et al.</i>
	US 5,874,577	02-23-1999	Chen, Wei <i>et al.</i>
	US 5,914,332	06-22-1999	Chen, Xiaoqi <i>et al.</i>
	US 6,072,053	06-06-2000	Vince, Robert <i>et al.</i>
	US 6,312,662	11-06-2001	Robinson, Edward D. <i>et al.</i>
	US 5,750,343	05-12-1998	Maag, Hans <i>et al.</i>
	US 6,767,900	07-27-2004	Ubasawa, Masaru <i>et al.</i>
	US 2001-031773	10-18-2001	Camden, James Berger
	US-2003-0109498	06-12-2003	Yuasa, Satoshi <i>et al.</i>

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)
	EP 0 267 050	05-11-1988	
	EP 0 441 192	01-25-1991	
	EP 0 465 297	01-08-1992	
	EP 0 531 597	03-17-1993	
	EP 0 632 048	01-04-1995	
	EP 0 786 455	07-30-1997	
	EP 0 852 233	07-08-1998	
	EP 0 919 562	06-02-1999	
	EP 1 295 879	03-26-2003	
	WO 88/06158	08-25-1988	
	WO 91/19721	12-26-1991	
	WO 92/00988	01-23-1992	
	WO 92/18520	10-29-1992	
	WO 93/12123	06-24-1993	
	WO 93/24510	12-09-1993	
	WO 96/14314	05-17-1996	
	WO 96/40156	12-19-1996	
	WO 98/04569	02-05-1998	
	WO 98/11906	03-26-1998	
	WO 99/62921	12-09-1999	
	WO 00/04033	01-27-2000	
	WO 01/13957	03-01-2001	

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)  
 \* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/



Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/583,573
<b>Filing Date</b>	June 19, 2006
<b>First Named Inventor</b>	Maria Fardis
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown

Sheet 2 of 6

01692.258US2

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)
	WO 01/17982	03-15-2001	
	WO 01/19320	03-22-2001	
	WO 01/46204	06-28-2001	
	WO 01/64693	09-07-2001	
	WO 01/96329	12-20-2001	
	WO 02/03997	01-17-2002	
	WO 02/06292	01-24-2002	
	WO 02/08241	01-31-2002	
	WO 02/14344	02-21-2002	
	WO 02/057425	07-25-2002	
	WO 02/100415	12-19-2002	
	WO 03/028737	04-10-2003	
	WO 03/050129	06-19-2003	
	WO 03/059255	07-24-2003	
	WO 03/064383	08-07-2003	
	WO 03/066005	08-14-2003	
	WO 03/080078	10-02-2003	
	WO 03/090690	11-06-2003	
	WO 2004/096234	11-11-2004	
	WO 2005/011709	02-10-2005	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).
	ABDEL-MEGUID, SHERIN S. <i>et al.</i> , Inhibition of Human Immunodeficiency Virus-1 Protease by a C <sub>2</sub> -Symmetric Phosphinate. Synthesis and Crystallographic Analysis, <i>Biochemistry</i> , 1993, 1543-1572, Vol. 32, No. 31.
	ALLEN, LEE F. <i>et al.</i> , CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK), <i>Seminars in Oncology</i> , October 2003, pp. 105-116, Vol. 30, No. 5, Elsevier Inc.
	BANTIA, SHANTA <i>et al.</i> , Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent, <i>International Immunopharmacology</i> , 2001, pp. 1199-1210, Elsevier Science B.V.
	BEAUCHAMP, LILIA M., <i>et al.</i> , Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase, <i>Journal of Medicinal Chemistry</i> , 1996, pp. 949-956, American Chemical Society.
	BOHANI D. W. <i>et al.</i> , A-420983: a potent, orally active inhibitor of Ick with efficacy in a model of transplant rejection, <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2004, Vol. 14.

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)

\* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 509. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/



Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/583,573
<b>Filing Date</b>	June 19, 2006
<b>First Named Inventor</b>	Maria Fardis
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown

Sheet 3 of 6

01692.258US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

<b>Examiner Initials*</b>	<b>Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u>, page(s) and (date).</b>
	BZOWSKA, AGNIESZKA <i>et al.</i> , Purine nucleoside phosphorylases: properties, functions, and clinical aspects, <i>Pharmacology &amp; Therapeutics</i> , 2000, pp. 349-425, Vol. 88, Elsevier Science Inc.
	CHAPMAN, H. <i>et al.</i> , Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, Vol. 20, Nos. 4-7, Marcel Dekker, Inc.
	CLARK, JEREMY L. <i>et al.</i> , Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection.
	CONKLYN, MARYROSE <i>et al.</i> , The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing, <i>Journal of Leukocyte Biology</i> , December 2004, pp. 1-8, Vol. 76, The Society for Leukocyte Biology.
	DE CLEREQ, E., Highlights in the Development of New Antiviral Agents, <i>Mini Reviews in Medicinal Chemistry</i> , 2002, 163-175, Vol. 2, No. 2., Bentham Science Publishers, Ltd.
	DE CLERCQ, ERIK, New Developments in Anti-HIV Chemotherapy, <i>Current Medicinal Chemistry</i> , 2001, 1543-1572, Vol. 8, No. 13, Bentham Science Publishers Ltd.
	DVORAKOVA, HANA <i>et al.</i> , Synthesis of 2'-Aminomethyl Derivatives of N-(2-(Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents, <i>J. Med. Chem.</i> , 1996, 3263-3268. Vol. 38, No. 17.
	EVANS, GARY B., Exploring Structure -- Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase, <i>J. Med. Chem.</i> , 2003, 3412-3423, Vol. 46, No. 15, American Chemical Society.
	GUMINA, GIUSEPPE <i>et al.</i> , Advances in antiviral agents for hepatitis B virus, <i>Antiviral Chemistry &amp; Chemotherapy</i> , 2001, 93-112, Vol. 12, Suppl. 1, International Medical Press.
	GOBEC, S. <i>et al.</i> , Phosphonate inhibitors of antigen 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall, <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, Vol. 14.
	HEGEDUS, LOUIS S. <i>et al.</i> , Synthesis of 4'-Methyl and 4'-cyano Carbocyclic 2',3'-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones, <i>J. Org. Chem.</i> , 2004, 8492-8495, Vol. 69, No. 24, American Chemical Society.
	HERCZEGH P., <i>et al.</i> , Osteoadsorbptive bisphosphonate derivatives of fluoroquinolone antibacterials, <i>J. Med. Chem.</i> , 2002, Vol. 45.
	HIRABAYASHI, HIDEKI <i>et al.</i> , Bone-Specific Drug Delivery Systems, <i>Clinical Pharmacokinetics</i> , 2003, 1319-1330, Vol. 42, No. 15.
	HOLY A. <i>et al.</i> , Synthesis, <i>Collect. Czech. Chem. Commun.</i> , 1989, Vol. 54, pages 2190-2210.
	JAIN, JUGNU <i>et al.</i> , Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5'-Monophosphate Dehydrogenase Inhibitor, <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 1272-1277, Vol. 302, No. 3, The American Society for Pharmacology and Experimental Therapeutics.
	KARPENKO, INNA L. <i>et al.</i> , Synthesis and Antitherapeutic Activity of Acyclovir Phosphonates, <i>NUCLEOSIDES, NUCLEOTIDES &amp; NUCLEIC ACIDS</i> , 2003, 319-328, Vol 22, No. 3, Marcel Dekker, Inc.


EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)

\* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/



Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/583,573
<b>Filing Date</b>	June 19, 2006
<b>First Named Inventor</b>	Maria Fardis
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown

Sheet 4 of 6

01692.258US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

<b>Examiner Initials*</b>	<b>Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).</b>
	KATO, KEISUKE <i>et al.</i> , Stereoselective synthesis of 4' - $\alpha$ -alkylcarbovir derivatives based on an asymmetric synthesis or chemo-enzymatic procedure, <i>Chemical &amp; Pharmaceutical Bulletin</i> , 1999, 1256-1264, Vol. 49, No. 9, Pharmaceutical Society of Japan.
	KATO, KEISUKE <i>et al.</i> , Enantio- and diastereoselective synthesis of 4'- $\alpha$ -substituted carbocyclic nucleosides, <i>Tetrahedron: Asymmetry</i> , 1998, 911-914, Vol. 9, Elsevier Science Ltd.
	KILPATRICK, J. MICHAEL, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2'-deoxyguanosine in primates, <i>International Immunopharmacology</i> , 2003, 541-548, Vol. 3, Elsevier Science B.V.
	KIM, CHOUNG UN <i>et al.</i> , Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycols: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against HIV, <i>J. Org. Chem.</i> , 1991, 2642-2647, Vol. 56, No. 8, American Chemical Society.
	KINSKY, STEPHEN C. <i>et al.</i> , Inhibition of cell proliferation by putative metabolites and non-degradable analogs of methotrexate- $\gamma$ -dimyristoylphosphatidylethanolamine, <i>Biochimica et Biophysica Acta</i> , 19878, 211-218, Vol. 917, No. 2., Elsevier Science Publishers B. V.
	KINSKY, STEPHEN C. <i>et al.</i> , Effect of liposomes sensitized with methotrexate- $\gamma$ -dimyristoylphosphatidylethanolamine on cells that are resistant to methotrexate, <i>Biochimica et Biophysica Acta</i> , 1986, 129-135, Vol. 885, Elsevier Science Publishers B.V.
	KINSKY, STEPHEN C. <i>et al.</i> , Circumvention of the methotrexate transport system by methotrexate-phosphatidylethanolamine derivatives effect of fatty acid chain length, <i>Biochimica et Biophysica Acta</i> , 1987, 96-103, Vol. 921, Elsevier Science Publishers B.V.
	KO, OK HYUN <i>et al.</i> , Efficient synthesis of novel carbocyclic nucleosides via sequential Claisen rearrangement and ring-closing metathesis, <i>Tetrahedron Letters</i> , 2002, 6399-6402, Vol. 43, Elsevier Science Ltd.
	LEWANDOWICZ, ANDRZEJ <i>et al.</i> , Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase, <i>The Journal of Biological Chemistry</i> , 2003, 31465-31468, Vol. 278, No. 34, The American Society for Biochemistry and Molecular Biology, Inc.
	MENENDEZ-ARIAS, LUIS <i>et al.</i> Targeting HIV: antiretroviral therapy and development of drug resistance, <i>TRENDS in Pharmacological Sciences</i> , 2002, 381-388, Vol. 23, No. 8, Elsevier Science Ltd.
	ONO-NITA, SUZANE KIOKO <i>et al.</i> , Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective against Wild-Type or Lamivudine-Resistant Hepatitis B Virus, <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 2602-2605, Vol. 46, No. 8, American Society for Microbiology.
	PANKIEWICZ, KRZYSZTOF W., Novel Mycophenolic Adenine Bis(phosphonate) Analogues As Potential Differentiation Agents against Human Leukemia, <i>J. Med. Chem.</i> , 2002 703-712, Vol. 45, No. 3, American Chemical Society.
	PARANG, KEYKAVOUS <i>et al.</i> , Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-Azido-2', 3'-dideoxythymidine (AZT), <i>Current Medicinal Chemistry</i> , 2000, 995-1039, Vol. 7, No. 10, Bentham Science Publishers Ltd.
	PRASHAD, MAHAVIR <i>et al.</i> , An Efficient and Large-Scale Enantioselective Synthesis of PNP405: A Purine Nucleoside Phosphorylase Inhibitor, <i>J. Org. Chem.</i> , 2002, 6612-6617, Vol. 67, No. 19, American Chemical Society.

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)

\* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/



Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/583,573
<b>Filing Date</b>	June 19, 2006
<b>First Named Inventor</b>	Maria Fardis
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown

Sheet 5 of 6

01692.258US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

<b>Examiner Initials*</b>	<b>Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).</b>
	RAY, ADRIAN S. <i>et al.</i> , Role of Purine Nucleoside Phosphorylase in Interactions between 2', 3'-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir, Antimicrobial Agents and Chemotherapy, 2004, 1089-1095, Vol. 48, No. 4, American Society for Microbiology.
	REED, LEFF <i>et al.</i> , Antidiabetic PPAR $\gamma$ Ligands: An update on Compounds in development, <i>Curr. Med. Chem. - Immun., Endoc. &amp; Metab. Agents</i> , 2002, 33-47, Vol. 2, No. 1, Bentham Science Publishers Ltd.
	ROBERTS, STANLEY M., Development of the route to the new anti-AIDS drug abacavir: A highlight of academic/industry liaison, <i>IDrugs</i> , 1998, 896-899, Vol. 1, No. 8, Current Drugs Ltd.
	ROSOWSKY, ANDRE <i>et al.</i> , METHOTREXATE ANALOGUES—27, <i>Biochemical Pharmacology</i> , 1986, 3327-3333, Vol. 35, No. 19, Pergamon Journals Ltd.
	ROSOWSKY, ANDRE <i>et al.</i> , Methotrexate Analogues, 32, Chain Extension, $\alpha$ -Carboxyl Replacement by Sulfonate and Phosphonate: Effect on Enzyme Binding and Cell-Growth Inhibition, <i>J. Med. Chem.</i> , 1988, 1326-1331, Vol. 31, No. 7, American Chemical Society.
	SCHULTZ, C., Prodrugs of biologically active phosphate esters, <i>Bioorganic &amp; Medicinal Chemistry</i> , 2003, 885-898, Vol. 11, Elsevier Science Ltd., GB.
	SEKIYA, KOUICHI <i>et al.</i> , 2-Amino-6-arylthio-9-[2-(phosphonomethoxy) ethyl] purine Bis(2,2,2-trifluoroethyl) Esters as Novel HBV-Specific Antiviral Reagents, <i>Journal of Medicinal Chemistry</i> , 2002, 3138-3142, Vol. 45, No. 14, American Chemical Society.
	SHI, WUXIAN <i>et al.</i> , <i>Plasmodium falciparum</i> Purine Nucleoside Phosphorylase, The Journal of Biological Chemistry, 2004, 18103-18106, Vol. 279, No. 18, The American Society of Biochemistry and Molecular Biology, Inc.
	SINTCHAK, MICHAEL D. <i>et al.</i> , The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors, <i>Immunopharmacology</i> , 2000, 163-184, Vol. 47, Elsevier.
	SRINIVAS, RANGA V. <i>et al.</i> , Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates, <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 2247-2250, Vol. 37, No. 10, American Society for Microbiology.
	STURTZ, GEORGES <i>et al.</i> , Su rne nouvelle approche de pharmacomodulation du methotrexate: synthese d'analogues gem-diphosphoniques d'amethopterine et de la N-10 deaza amethopterine, <i>Medicinal Chemistry, C. R. Acad. Sci. Paris</i> , 1990, Vol. 10, No. 2, 739-742, Academie des Sciences.
	STURTZ, GEORGES <i>et al.</i> , Analogues phosphonoglutamiques d'amethopterine (methotrexate), <i>Eur. J. Med. Chem - Chim. Ther.</i> , 1984, 267-273, Vol. 19, No. 3.
	STURTZ, G. <i>et al.</i> , Synthesis of gem-bisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma, <i>Eur. J. Med. Chem.</i> , 1993, 899-903, Vol. 28, Elsevier.
	STURTZ, G. <i>et al.</i> , A study of the delivery-targeting concept applied to antineoplastic drugs active on human osteosarcoma, I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues, <i>Eur J. Med. Chem.</i> , 1992, 825-833, Vol. 27, No. 8, Elsevier.
	VIELHABER, BERND, Bericht vom 3rd International Workshop on Salvage Therapy for HIV-Infection, <i>Deutsche Aids-Hilfe e.V. FaxReport zu HIV und AIDS</i> , 2000, 12-14.
	WAEGELL W. <i>et al.</i> A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection, <i>Transplantation Proceedings</i> , 2002, 1411-1417, Vol. 34.

EXAMINER

DATE CONSIDERED


Substitute Information Disclosure Statement Form (PTO-1449)

\* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 608. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

Receipt date: 11/02/2006

10583573 - GAU: 1623



Substitute for form 1449A/PTO and/or 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	10/583,573
<b>Filing Date</b>	June 19, 2006
<b>First Named Inventor</b>	Maria Fardis
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown

Sheet 6 of 6

01692.258US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	WROBLEWSKI, ANDRZEJ <i>et al.</i> , Synthesis of (1R,2S)- and (1S,2S)-3-(4-carbamoyl-1,2,3-triazol-1-yl)-1,2-dihydroxypropylphosphonates, Tetrahedron: Asymmetry, 2004, 1457-1464, Vol. 15, Elsevier.

EXAMINER

/Traviss McIntosh III/ (03/28/2010)

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)  
 \* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/